Survival in Peritoneal Carcinomatosis: Prognostic Factors and Treatments

A Condition That Was Once Considered Terminal

Until the 1990s, peritoneal carcinomatosis was universally considered a terminal condition equivalent to widespread distant metastasis. The introduction of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) by Paul Sugarbaker revolutionised this paradigm, demonstrating that long-term survival and even cure are achievable for selected patients.

Survival Data by Primary Tumour Origin

Colorectal carcinomatosis: Median survival 40–60 months with CRS+HIPEC at expert centres versus 12–24 months with systemic chemotherapy alone. 5-year survival 30–45% in selected patients. Ovarian carcinomatosis: Complete cytoreduction with HIPEC associated with improved progression-free survival. 5-year survival 30–50% in optimally cytoreduced patients. Appendiceal/pseudomyxoma peritonei: Near-curative outcomes possible. 5-year survival exceeds 70–85% for mucinous appendiceal carcinomas. Mesothelioma: Significant survival benefit compared to systemic therapy alone in carefully selected patients.

Key Prognostic Factors

Completeness of cytoreduction (CC-0): The single most important predictor. Patients with no visible residual disease have dramatically better survival. Peritoneal Cancer Index (PCI): Lower score predicts better outcomes. Primary tumour biology: Grade, histological subtype, molecular features. Response to pre-operative chemotherapy. Centre volume and expertise: High-volume specialised centres consistently achieve better outcomes.

Quality of Life After CRS+HIPEC

Recovery takes 6–12 weeks. Quality of life returns to baseline in most patients by 3–6 months post-surgery. Long-term survivors report good quality of life comparable to the general population. The key message: for selected patients, the potential long-term benefit justifies the short-term morbidity of this major procedure.